CoChat

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Open access
Li, Chunxiao, Xu, Xiaofei, Wei, Shuhua, Jiang, Ping, Xue, Lixiang, Wang, Junjie · 2021 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.

Abstract

Macrophages are the most important phagocytes in vivo. However, the tumor microenvironment can affect the function and polarization of macrophages and form tumor-associated macrophages (TAMs). Usually, the abundance of TAMs in tumors is closely associated with poor prognosis. Preclinical studies have identified important pathways regulating the infiltration and polarization of TAMs during tumor progression. Furthermore, potential therapeutic strategies targeting TAMs in tumors have been studied, including inhibition of macrophage recruitment to tumors, functional repolarization of TAMs toward an antitumor phenotype, and other therapeutic strategies that elicit macrophage-mediated extracellular phagocytosis and intracellular destruction of cancer cells. Therefore, with the increasing impact of tumor immunotherapy, new antitumor strategies to target TAMs are now being discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001341

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The distribution of macrophages in different tissues and organs. Macrophages are heterogeneous, showing different names, specific transcription factors and markers. Here, different colors correspond to different items, yellow for names, green for transcription factors and red for markers. IL-6, interleukin 6; MG, mammary gland; PC, peritoneal cavity; TGF-ß, transforming growth factor-β.
Figure 1 The distribution of macrophages in different tissues and organs. Macrophages are heterogeneous, showing different names, specific transcription factors and markers. Here, different colors correspond to different items, yellow for names, green for transcription factors and red for markers. IL-6, interleukin 6; MG, mammary gland; PC, peritoneal cavity; TGF-ß, transforming growth factor-β.CC BY-NC · PubMed Central
Figure 2 History of macrophages in cancer. Advances made over the past decades in the identification of macrophages including checkpoints and stimulatory signals. IFNγ, interferon-γ; IL-10, interleukin 10; PD-1, programmed cell death protein 1; SIRPα, signal regulatory protein α; TAMs, tumor-associated macrophage; TGF-β, transforming growth factor-β.
Figure 2 History of macrophages in cancer. Advances made over the past decades in the identification of macrophages including checkpoints and stimulatory signals. IFNγ, interferon-γ; IL-10, interleukin 10; PD-1, programmed cell death protein 1; SIRPα, signal regulatory protein α; TAMs, tumor-associated macrophage; TGF-β, transforming growth factor-β.CC BY-NC · PubMed Central
Figure 3 Macrophages can be polarized into M1 and M2 macrophages with different mechanisms. Macrophages can be polarized into two functional categories: classically activated macrophages (M1) and alternatively activated macrophages (M2) under different stimuli through different transcription factors, and show distinct specific markers on the macrophage subsets, which play important roles in pro-inflammation or anti-inflammation. FcR, Fc receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL10, interleukin 10; LPS, lipopolysaccharide; miRNA, microRNA; NF-κB, nuclear factor-kappa B; STAT1, signal transducer and activator of transcription 1; TGF-ß, transforming growth factor-β; TLR, toll-like receptor; TNFα, tumor necrosis factor-α.
Figure 3 Macrophages can be polarized into M1 and M2 macrophages with different mechanisms. Macrophages can be polarized into two functional categories: classically activated macrophages (M1) and alternatively activated macrophages (M2) under different stimuli through different transcription factors, and show distinct specific markers on the macrophage subsets, which play important roles in pro-inflammation or anti-inflammation. FcR, Fc receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL10, interleukin 10; LPS, lipopolysaccharide; miRNA, microRNA; NF-κB, nuclear factor-kappa B; STAT1, signal transducer and activator of transcription 1; TGF-ß, transforming growth factor-β; TLR, toll-like receptor; TNFα, tumor necrosis factor-α.CC BY-NC · PubMed Central
Figure 4 Overview of macrophages involvement in myeloid cell differentiation in cancer through blood circulation. Macrophages development, accumulation, suppressive activity and survival are controlled by a complex network of transcription factors, cytokines and non-cytokine immune regulatory factors. Monocytes and M-MDSCs originate from the common myeloid progenitor (CMP) cell in the bone marrow (also in the spleen of mice) during myelopoiesis (left). They can circulate in the blood and lymph node and home to sites of inflammation and to the solid tumors (right). Under different conditions such as the tumor microenvironment, a variety of factors promote cancer risk, facilitate cancer onset and progression, and polarize TAMs. DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin; NF-κB, nuclear factor-kappa B; MDSCs, Myeloid-derived suppressor cells; TAMs, tumor-associated macrophages; TNFα, tumor necrosis factor-α; VEGF, vascular epidermal growth factor.
Figure 4 Overview of macrophages involvement in myeloid cell differentiation in cancer through blood circulation. Macrophages development, accumulation, suppressive activity and survival are controlled by a complex network of transcription factors, cytokines and non-cytokine immune regulatory factors. Monocytes and M-MDSCs originate from the common myeloid progenitor (CMP) cell in the bone marrow (also in the spleen of mice) during myelopoiesis (left). They can circulate in the blood and lymph node and home to sites of inflammation and to the solid tumors (right). Under different conditions such as the tumor microenvironment, a variety of factors promote cancer risk, facilitate cancer onset and progression, and polarize TAMs. DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin; NF-κB, nuclear factor-kappa B; MDSCs, Myeloid-derived suppressor cells; TAMs, tumor-associated macrophages; TNFα, tumor necrosis factor-α; VEGF, vascular epidermal growth factor.CC BY-NC · PubMed Central
Figure 5 Immunoregulatory effects of TAMs. TAMs in TME can exert the immune regulatory roles on the different immune cells with different mechanisms by producing a variety of cytokines and effector molecules. On the one hands, TAMs inhibit T cell, B cells, NK cells and DCs. On the other hands, TAMs can promote Tregs, Th17 cells, γδT cells and MDSCs, as well as angiogenesis and metastasis of tumor. DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin; MDSCs, Myeloid-derived suppressor cells; NK, nuclear factor-kappa B; PD-1, programmed cell death protein 1; TAMs, tumor-associated macrophages; TGFβ, transforming growth factor-β; TME, tumor microenvironment; TNFα, tumor necrosis factor-α; VEGF, vascular epidermal growth factor.
Figure 5 Immunoregulatory effects of TAMs. TAMs in TME can exert the immune regulatory roles on the different immune cells with different mechanisms by producing a variety of cytokines and effector molecules. On the one hands, TAMs inhibit T cell, B cells, NK cells and DCs. On the other hands, TAMs can promote Tregs, Th17 cells, γδT cells and MDSCs, as well as angiogenesis and metastasis of tumor. DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin; MDSCs, Myeloid-derived suppressor cells; NK, nuclear factor-kappa B; PD-1, programmed cell death protein 1; TAMs, tumor-associated macrophages; TGFβ, transforming growth factor-β; TME, tumor microenvironment; TNFα, tumor necrosis factor-α; VEGF, vascular epidermal growth factor.CC BY-NC · PubMed Central
Figure 6 Main therapeutic strategies targeting TAMs. These therapeutic ways are aimed at either activating the anti-tumoral activity, or inhibiting the recruitment, survival and protumoral functions of macrophages. The process of macrophage-mediated antibody-dependent cellular cytotoxicity (ADCC) involves recognition of the therapeutic antibodies by Fc receptors (FcRs) on TAMs. The ‘don’t eat me’ signal including SIRPα-CD47 pathway and CD24-Siglec 10 pathway. The antibodies against SIRPα-CD47 pathway and CD24-Siglec 10 pathway can activate macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Here, the main therapeutic strategies targeting TAMs are generally summarized including the ‘don’t eat me’ signal pathways, repolarization, reducing and decreasing the recruitment and survival, and immune-checkpoints blockades with antibodies. IFNR, interferon receptor; TAMs, tumor-associated macrophages; VEGFR, vascular epidermal growth factor R.
Figure 6 Main therapeutic strategies targeting TAMs. These therapeutic ways are aimed at either activating the anti-tumoral activity, or inhibiting the recruitment, survival and protumoral functions of macrophages. The process of macrophage-mediated antibody-dependent cellular cytotoxicity (ADCC) involves recognition of the therapeutic antibodies by Fc receptors (FcRs) on TAMs. The ‘don’t eat me’ signal including SIRPα-CD47 pathway and CD24-Siglec 10 pathway. The antibodies against SIRPα-CD47 pathway and CD24-Siglec 10 pathway can activate macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Here, the main therapeutic strategies targeting TAMs are generally summarized including the ‘don’t eat me’ signal pathways, repolarization, reducing and decreasing the recruitment and survival, and immune-checkpoints blockades with antibodies. IFNR, interferon receptor; TAMs, tumor-associated macrophages; VEGFR, vascular epidermal growth factor R.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 221 references

Research works printed but not linked: 1

  1. Metchnikoff, 1883, Untersuchungen über die mesodermalen Phagocyten einiger Wirbeltiere, Biologisches centralblatt, 3, 560

Cited by

See all 365

Metadata

Authors
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J.
Affiliations
Peking University Third Hospital (CN)
Corresponding author
  • Li, Chunxiao
  • Jiang, Ping
  • Xue, Lixiang
  • Wang, Junjie
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-01
Volume
9
Issue
1
Pages
e001341
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3124610114
Cited by
360
References
221
Citations by year
2026: 59 · 2025: 111 · 2024: 90 · 2023: 60 · 2022: 33 · 2021: 6
FWCI
4.98
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81803051)
  • China Postdoctoral Science Foundation (2017M620545, 2018T110015)
  • Natural Science Foundation of Beijing Municipality (7192220)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
tumor-associated macrophages, macrophage polarization, tumor microenvironment, TAM infiltration, TAM-targeted therapy, TAM repolarization, phagocytosis, cancer immunotherapy, prognosis
MeSH terms
Tumor-Associated Macrophages, Antineoplastic Agents, Humans, Neoplasms, Phagocytosis, Prognosis, Cell Polarity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. https://app.cochat.ai/papers/10.1136/jitc-2020-001341
The paper
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021). Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.